For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
17
views
0
references
 Top references
cited by
2
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      153
      similar
       All similar

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Lipoprotein (a) Levels in End-Stage Renal Failure and Renal Transplantation

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Some previous studies have documented an increase in lipoprotein (a) [Lp(a)] levels in renal diseases. Here, we report data in subjects with end-stage renal failure treated with hemodialysis (HD) or with continuous ambulatory peritoneal dialysis (CAPD) and in renal transplant recipients (RTR), compared with a group of normolipidemic controls (C). Lp(a) levels were significantly increased in HD and CAPD patients in comparison with C, while they were only slightly increased in RTR. Both HD and CAPD patients showed Lp(a) levels higher than in RTR, but no difference was found between the subjects of the two dialysis procedures. The prevalence of Lp(a) levels > 25 mg/dl was significantly higher in HD and CAPD patients, but not in RTR, in comparison with C. Moreover, Lp(a) levels did not change after HD. When patients were divided according to their fasting lipid levels in normolipidemics and hyperlipoproteinemics, no difference was found for Lp(a) levels in any group. Mechanisms underlying the increase in Lp(a) levels in these patients are not known. It is possible to suggest an active role of the kidney in the Lp(a) metabolism or that uremic plasma contains some factors affecting Lp(a) metabolism.

          Related collections

          Author and article information

          Journal
          Journal ID (publisher-id): NEF
          Journal ID (nlm-ta): Nephron
          Journal ID (doi): 10.1159/issn.1660-8151
          Title: Nephron
          Publisher: S. Karger AG
          ISSN (Print): 1660-8151
          ISSN (Electronic): 2235-3186
          Publication date Subscription-year: 1993
          Publication date (Print): 1993
          Publication date (Electronic): 12 December 2008
          Volume: 64
          Issue: 4
          Pages: 560-564
          Affiliations
          aCattedra di Patologia Medica, Università di Palermo; bDivisione di Nefrologia, Ospedale Civico, USL58; cCattedra di Patologia Chirurgica, Università di Palermo, Italia.
          Article
          Publisher ID: 187400 Other ID: Nephron 1993;64:560–564
          DOI: 10.1159/000187400
          PubMed ID: 8366981
          SO-VID: 3bb23230-d53e-4ba0-b7ee-98efbac220df
          Copyright © © 1993 S. Karger AG, Basel
          License:

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Date accepted : 08 August 1992
          Page count
          Pages: 5
          Categories
          Subject: Original Paper

          ScienceOpen disciplines: Cardiovascular Medicine,Nephrology
          Keywords: End-stage renal failure,Renal transplantation,Lipoprotein (a)
          Data availability:
          ScienceOpen disciplines: Cardiovascular Medicine, Nephrology
          Keywords: End-stage renal failure, Renal transplantation, Lipoprotein (a)

          Comments

          Comment on this article

          scite_

          Similar content153

          See all similar

          Cited by2

          See all cited by